CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …
promising immunotherapeutic approach to fight cancers. This approach consists of …
Targeting the tumor stroma for cancer therapy
M Xu, T Zhang, R Xia, Y Wei, X Wei - Molecular Cancer, 2022 - Springer
Tumors are comprised of both cancer cells and surrounding stromal components. As an
essential part of the tumor microenvironment, the tumor stroma is highly dynamic …
essential part of the tumor microenvironment, the tumor stroma is highly dynamic …
Inflammation and tumor progression: signaling pathways and targeted intervention
H Zhao, L Wu, G Yan, Y Chen, M Zhou… - Signal transduction and …, 2021 - nature.com
Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …
either promotes or suppresses tumor progression, potentially displaying opposing effects on …
Macrophage-based approaches for cancer immunotherapy
Adoptive cell therapy with genetically modified T cells has generated exciting outcomes in
hematologic malignancies, but its application to solid tumors has proven challenging. This …
hematologic malignancies, but its application to solid tumors has proven challenging. This …
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the
treatment of advanced cancers. However, the tumor microenvironment (TME) functions as a …
treatment of advanced cancers. However, the tumor microenvironment (TME) functions as a …
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D Fukumura, J Kloepper, Z Amoozgar… - Nature reviews Clinical …, 2018 - nature.com
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …
however, the majority of patients with cancer do not derive benefit from these treatments …
Monocytes in the tumor microenvironment
S Ugel, S Canè, F De Sanctis… - Annual Review of …, 2021 - annualreviews.org
Immunotherapy has revolutionized cancer treatment over the past decade. Nonetheless,
prolonged survival is limited to relatively few patients. Cancers enforce a multifaceted …
prolonged survival is limited to relatively few patients. Cancers enforce a multifaceted …
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
M Huang, Y Lin, C Wang, L Deng, M Chen… - Drug resistance …, 2022 - Elsevier
Angiogenesis is a hallmark of cancer and is required for tumor growth and progression.
Antiangiogenic therapy has been revolutionarily developing and was approved for the …
Antiangiogenic therapy has been revolutionarily developing and was approved for the …
Monocyte heterogeneity and functions in cancer
Monocytes are innate immune cells of the mononuclear phagocyte system that have
emerged as important regulators of cancer development and progression. Our …
emerged as important regulators of cancer development and progression. Our …
Normalizing function of tumor vessels: progress, opportunities, and challenges
Abnormal blood and lymphatic vessels create a hostile tumor microenvironment
characterized by hypoxia, low pH, and elevated interstitial fluid pressure. These …
characterized by hypoxia, low pH, and elevated interstitial fluid pressure. These …